Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry

Abstract

Objective:

The purpose of this study was to investigate outcomes of patients treated with prasugrel or clopidogrel after percutaneous coronary intervention (PCI) in a nationwide acute coronary syndrome (ACS) registry.

Background:

Prasugrel was found to be superior to clopidogrel in a randomized trial of ACS patients undergoing PCI. However, little is known about its efficacy in everyday practice.

Methods:

All ACS patients enrolled in the Acute Myocardial Infarction in Switzerland (AMIS)-Plus registry undergoing PCI and being treated with a thienopyridine P2Y₁₂ inhibitor between January 2010–December 2013 were included in this analysis. Patients were stratified according to treatment with prasugrel or clopidogrel and outcomes were compared using propensity score matching. The primary endpoint was a composite of death, recurrent infarction and stroke at hospital discharge.

Results:

Out of 7621 patients, 2891 received prasugrel (38%) and 4730 received clopidogrel (62%). Independent predictors of in-hospital mortality were age, Killip class >2, STEMI, Charlson comorbidity index >1, and resuscitation prior to admission. After propensity score matching (2301 patients per group), the primary endpoint was significantly lower in prasugrel-treated patients (3.0% vs 4.3%; p=0.022) while bleeding events were more frequent (4.1% vs 3.0%; p=0.048). In-hospital mortality was significantly reduced (1.8% vs 3.1%; p=0.004), but no significant differences were observed in rates of recurrent infarction (0.8% vs 0.7%; p=1.00) or stroke (0.5% vs 0.6%; p=0.85). In a predefined subset of matched patients with one-year follow-up (n=1226), mortality between discharge and one year was not significantly reduced in prasugrel-treated patients (1.3% vs 1.9%, p=0.38).

Conclusions:

In everyday practice in Switzerland, prasugrel is predominantly used in younger patients with STEMI undergoing primary PCI. A propensity score-matched analysis suggests a mortality benefit from prasugrel compared with clopidogrel in these patients.

Keywords

Acute coronary syndrome thienopyridines platelet aggregation inhibitors propensity score percutaneous coronary intervention

Get full access to this article

View all access options for this article.

References

Yusuf

Zhao

Mehta

Chrolavicius

Tognoni

Fox

KK.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.

Serebruany

Steinhubl

Berger

Malinin

Bhatt

Topol

EJ.

Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45: 246–251.

Mega

Wiviott

. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354–362.

Bellemain-Appaix

Brieger

Beygui

. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. JAmCollCardiol. 2010; 56: 1542–1551.

Kurz

Eberli

FR.

Medical therapy of coronary artery disease after percutaneous intervention. Curr Opin Pharmacol 2013; 13: 287–293.

Wiviott

Braunwald

McCabe

. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

Roe

Armstrong

Fox

. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297–1309.

Hamm

Bassand

Agewall

. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.

Steg

James

Atar

. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.

10.

Jneid

Anderson

Wright

. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875–910.

11.

O’Gara

Kushner

Ascheim

. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362–e425.

12.

Radovanovic

Erne

AMIS Plus: Swiss registry of acute coronary syndrome. Heart 2010; 96: 917–921.

13.

Radovanovic

Seifert

Urban

. Validity of Charlson comorbidity index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart 2013; 100: 288–294.

14.

Sekhon

SJ.

Multivariate and propensity score matching software with automated balance optimization: The Matching package for R. J Stat Softw 2011; 42: 1–52.

15.

Granger

Goldberg

Dabbous

. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.

16.

Kurz

Bernstein

Hunt

. Simple point-of-care risk stratification in acute coronary syndromes: The AMIS model. Heart 2009; 95: 662–668.

17.

Wiviott

Antman

Winters

. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366–3373.

18.

Wiviott

Trenk

Frelinger

. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923–2932.

19.

Roe

Goodman

Ohman

. Elderly patients with acute coronary syndromes managed without revascularization: Insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013; 128: 823–833.

20.

Riesmeyer

Salazar

Weerakkody

. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol 2012; 52: 789–797.

21.

Sherwood

Wiviott

Peng

. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: Insights from the National Cardiovascular Data Registry. J Am Heart Assoc 2014; 3: e000849.

22.

Damman

Varenhorst

Koul

. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)). Am J Cardiol 2014; 113: 64–69.

23.

Diaz de la Llera

Cubero Gomez

Rangel

. A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. J Interv Cardiol 2013; 26: 463–469.

24.

De Luca

Suryapranata

Stone

. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA 2005; 293: 1759–1765.

25.

Guagliumi

Stone

Cox

. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: Results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004; 110: 1598–1604.

26.

Montalescot

Barragan

Wittenberg

. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.

27.

Tcheng

Kandzari

Grines

. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003; 108: 1316–1323.

28.

Roffi

Chew

Mukherjee

. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J 2002; 23: 1441–1448.

29.

Simoons

ML.

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–1924.

30.

Cutlip

Windecker

Mehran

. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351.